Cooperation partners
-
Exclusive license for the commercialization of GLP-1 products in China
-
Exclusive license to develop and commercialize programmed therapeutic cells in Greater China
-
Exclusive license for the distribution and promotion of insulin products
-
Collaboration for clinical development and commercialization of MCM1 in China
-
Exclusive partnership to commercialize liposomal products utilizing NanoX™ in Mainland China
-
快盈500Priority for potential licensing or development of two ophthalmic-related disease products
-
Exclusive right to develop and commercialize Remitch in China
-
快盈500Partnership focused on the development and commercialization of novel bi- and multi-specific antibodies in the field of immuno-oncology
-
Collaboration for clinical development and commercialization of multiple biosimilars in China
-
Potential licensing priorities for four inner ear disease related research products
-
快盈500Investment to research and develop early stage cancer drugs